Mylan NV (NASDAQ : MYL ), a global pharmaceutical company, has launched its Dalfampridine Extended-Release Tablets, 10mg, the authorised generic version of Acorda's Ampyra, in the United States, it was reported on Friday.
The product is indicated to improve walking in adult patients with multiple sclerosis.
The launch comes after the United States Court of Appeals for the Federal Circuit upheld the United States District Court for the District of Delaware's decision to invalidate four Ampyra patents, US Patent Nos 8,663,685, 8,007,826, 8,440,703, and 8,354,437. Acorda's US Patent No 5,540,938, previously upheld by the District Court, expired on 30 July 2018.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream